Abstract PS4-12-24: Risk and Pattern of Relapse in Triple-Negative Breast Cancer with Pathological Complete Response after Neoadjuvant Treatment: Updated Results from the European GAMBIT Real-world Study

Clinical Cancer Research 2026

View at publisher
Authors: M. Dieci, T. Foukakis, S.O. Giacchetti, Christine Desmedt, J. Frenel, Elisa Gasparini, M. Kok, Paolo Giovanni Vigneri, W. Jacot, C. Vernieri, M. Lambertini, Francesca Patanè
+27 more F. Piacentini, E. Bria, A. Zambelli, Dario Trapani, A. Botticelli, O. Garrone, D. Massa, S. Lando, A. Matikas, Laetitia Someil, G. Floris, Mario Campone, Moira Ragazzi, E. Lips, Federica Martorana, Giorgio Bonomi, Andri Papakostantinou, L. Nicolé, I. Zerdes, P. Neven, Martina Rotolo, H. Horlings, Sabrina Nucera, A. Gudin de Vallerin, A. Vingiani, A. Dei Tos, V. Guarneri
DOI: 10.1158/1557-3265.sabcs25-ps4-12-24
Cited by: 1

Abstract

Abstract Background: Pathological complete response (pCR) after neoadjuvant treatment (NAT) associates with improved outcomes in triple-negative breast cancer (TNBC), yet a subset of patients still experience relapse. We previously reported on risk and pattern of relapse in up to 733 patients with pCR after NAT (Massa D, SABCS 2024 and ESMO Breast 2025). Here, we present updated results on 1190 patients, with detailed analysis of site-specific relapse risk. Patients and Methods: 2458 patients with stage I-III TNBC (ER

Fields of Study & Subjects

Breast Cancer Treatment Studies Advanced Breast Cancer Therapies Breast Lesions and Carcinomas

Publication details

Journal / source
Clinical Cancer Research
Publisher
American Association for Cancer Research (AACR)
Volume
32
Issue
4_Supplement
Pages
PS4–12
Publication date
17 February 2026
Language
EN